Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 49 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 49 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. Biochemistry Laboratory, Faculty of Medicine, Aristotle University, Thessaloniki, Greece

2. Department of Thalassaemia, AXEPA University Hospital, Thessaloniki, Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Nenova K., Karamouzis M., Kovatchev D., Dimitriadou A., Tzekov H.: Tumor markers monitoring for lung cancer chemotherapy assessment. Ann. Proc. Inter. Med. Ass. 1(1): 74-77 (1995)

3. Karamouzis M., Hatziantoniou S., Giannoulis E., Nikopoulos A., Dimitriadou-Vafiadou Α.: The tumor marker CA 19-9- and CEA in Symptomatic patient suspected of having pancreatic cancer. Scientific Annuals of the Faculty of Medicine, Aristotle University of Thessaloniki 192: 63-70 (1992)

4. Arvanitaki C., Nikopoulos Α., Giannoulis E., Karamouzis M., Semoglou E., Theoharidis Α., Tourkantonis A.: Evaluation of tumor marker CA 19-9 in Diagnosis of Cancer of the pancreas. Proceedings of Tumor Associated Antigens, Oncologes Receptors, Cytocines in tumor Diagnosis and therapy at the Beginning of the Nineties 8:16-19 (1991) Edited by Keapdol R., W, Zucksh, Werdt Verelae. Munchen, Bern. Wien, New York (1991)

5. Harlozinska A., Sedlaczek P., Van Dalen A., Rozdoeski K. and Einarsson R. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasmas. Anticancer Res. 17: 4473-4478 (1997)

6. Rainer Klapdor (ed.): Tumor Markers in Clinical Oncology and Overview. Sorin Medica Torino, 1994

7. Karamouzis M., Hrisogonidis J., Vritzios A., Dimitriadou-Vafiadou A.: Our experience of the comparison of CA 15-3 and CEA levels in women’s serum with breast cancer. Scientific annuals of the faculty of medicine 192: 55-62 (1992)

8. Colomer R., Ruibal Α., Navarro M., Encabo G. Sole L.A.: Circulating CA 15-3 levels in breast cancer our present experience. Int. J. Biol Markers 1: 89-92 (1987)

9. Gion M., MIone R., Leon A., Dittadi R.: Comparison of diagnostic accuracy of CA 28.29 and CA15.3 in primary breast Cancer. Clin. Chem. 45: 5:630-637 (1999)

10. Cazin J.L., Gosselin P., Boniface B., Demaile M.C., Demalle A.: An evaluation of CA 549, a circulating marker of breast cancer using a procedure for comparison with CA 15-3. Anticancer Res. 12: 719-724 (1992)

11. Klug T.L.: Monoclonal antibody immunoradiometric assays for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res.  44: 1048 (1984)

12. Meisel M., Setraube W., Weise L., Burkhardt B.: A study of serum Casa and CA125 levels in patients with ovarian carcinoma. Arch. Gynecol. Obstet. 256: 9-15 (1995)

13. Ward B.G., McGuckin M.A., Ramm L.E., et al.: The management of ovarian carcinoma is improved by the use of cancer associated serum antigen (CASA) and CA 125 assays. Cancer 71: 430-438 (1993)

14. Hogdall C.L., Hogdall Est., Hording U.L., et al.: Use of tetranectin, CA 125 and casa to predict residual tumor and survival at second and third look operation to ovarian cancer. Acta Oncologica  35(1): 63-69 (1996)

15. Schlom J.: Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal Foundation Award Lecture: Cancer Res. 46: 3225 (1986)

16. Grefen H., Klapdor R.: New Tumor Associated Antigens Georg. Thieme/ Verlag Stuttgart. New York, 1984

17. Barillci P., Ramaciato G., Angelis R., Gozzo P., Aurello P., Indinnimeo M., Valabrega S., D’ Angelo R, Fegiz G.: The role of CEA, TPA and CA 19-9 in the early defection of reccurent Colotrectal Cancer. Int. J. Col. Dis 4: 230-233 (1989)

18. Kaws S., Kato M., Hsue GL, et al.: Clinical evaluation of pagreatic cancer associated mucin expressing CA 19-9, CA 50, span-1, sialy SSEA-1 and dupan-2. Scand. J. Gastroenterol.  27: 635-643 (1992)

19. Symeonidis A., Kouranlis-Symeonidis A., Constantinidou I., et al.: Increased CA 15-3 levels in the serum of patients with homozygous β-Thalassaemia and sickle cell/β-thalassaemia. Br. J. Hematol. 133: 690-694 (2006)

20. Christoforidis A., Lefkou E., Vlachani E., et al.: Evaluation of serum tumor markers concentrations in patients with homozygous β-Thalassaemia in relation to demographical. Clin. Biochem. Param. Ann. Hematol. 86: 837-841 (2007)

21. Boga C., Ozdogu H., Sezgin N., Kizilkilic E., Koc Z., Sakalli H., Yalcintas D., Kozanoglu I.: Serum cancer antigen 15-3 concentrations in patients with sickle cell disease. Br. J. Haematol. 134: 546-547 (2006)

22. Baldus S.E., Hanisch F.G., Putz G., Flucke U., Monig S.P., Schneider P.M., Thiele J., Holscher A.H., Dienes H.P.: Immunoreactivity of Lewis Blood group and mucin peptide core antigens: correlations with grade of dysplasia and malignant transformation in the colorectal adenoma-carcinoma sequence. Histol. Histopathol. 17: 191-198 (2002)

23. Hebbel R.P., Osarogiagbon R., Kaul D.:  The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11: 129-151 (2004)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr